InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Radiopharm Theranostics Ltd

RADX Clue Score42
Australia Fiscal year ends June CIK 0001949257
$1.20 +8.10% Close, 13 Oct 2026
Alert on the numbers Alert on insider trades
Price $1.20 −83.10% Close, 13 Oct 2026

Closing prices at the end of each trading day, from 5 Dec 2024. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2023Revenue0.3Operating income−34.5Net income−34.6EPS, diluted−11.32Fiscal year 2024Revenue0.3 +2.3%Operating income−47.2Net income−47.9EPS, diluted−12.41Fiscal year 2025Revenue3.6 +1,114.3%Operating income−38.2Net income−38.3EPS, diluted−1.76
FY2023FY2024FY2025
Revenue 0.3 0.3 3.6
Growth +2.3% +1,114.3%
Operating income −34.5 −47.2 −38.2
Net income −34.6 −47.9 −38.3
Growth
EPS, diluted −11.32 −12.41 −1.76

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Gross marginOperating marginNet margin
Fiscal year 2023Gross margin100.0%Operating margin−11,796.1%Net margin−11,838.6%Free cash flow margin−7,951.6%Fiscal year 2024Gross margin100.0%Operating margin−15,777.2%Net margin−16,024.3%Fiscal year 2025Gross margin1.1%Operating margin−1,050.6%Net margin−1,055.3%
FY2023FY2024FY2025
Gross margin 100.0% 100.0% 1.1%
Operating margin −11,796.1% −15,777.2% −1,050.6%
Net margin −11,838.6% −16,024.3% −1,055.3%
Free cash flow margin −7,951.6% n/a n/a

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2023Operating cash flow−23.2Capital expenditure−0.0Free cash flow−23.2Fiscal year 2024Operating cash flow−23.0Fiscal year 2025Operating cash flow−36.6
FY2023FY2024FY2025
Operating cash flow −23.2 −23.0 −36.6
Capital expenditure −0.0 n/a n/a
Free cash flow −23.2 n/a n/a
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash and securities
Fiscal year 2023Cash and securities11.7Shareholders’ equity45.6Fiscal year 2024Cash and securities18.6Shareholders’ equity27.4Fiscal year 2025Cash and securities29.1Shareholders’ equity42.9
FY2023FY2024FY2025
Cash and securities 11.7 18.6 29.1
Shareholders’ equity 45.6 27.4 42.9

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Balance sheet

In millions of USD, except per-share figures; shares in millions. Fiscal years ending June, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2023 30 Jun 2023 FY2024 30 Jun 2024 FY2025 30 Jun 2025
Assets
11.7 18.6 29.1
4.5 1.0 10.4
n/a 0.1 0.1
n/a 72.0 86.5
Growth +20.1%
Liabilities
n/a 44.7 43.6
Equity
45.6 27.4 42.9
Growth −40.0% +56.7%
Per share and net cash
n/a n/a 2,365
calc n/a n/a 0.02

Lines marked calc are worked out here from filed figures; point at one for how.